You are a medical publication professional in a pharmaceutical company, working on a clinical trial publication for a novel drug that has the potential to revolutionize the treatment of a life-threatening disease. Some of the authors are keen to emphasize the promising efficacy outcomes without, in your opinion, incorporating the same level of detail about certain adverse events. What Would You Do?
